Heliospectra Q2 2024: Weaker sales, minor deviations elsewhere - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Heliospectra Q2 2024: Weaker sales, minor deviations elsewhere - Redeye

{newsItem.title}

Redeye comments on Heliospectra’s Q2 results, noting that sales were weaker than expected due to short-term delays and the timing of orders. However, order intake and operating expenses were in line with our forecast. The key highlight is the optimistic short-term outlook.

Länk till analysen i sin helhet: https://www.redeye.se/research/1033964/heliospectra-q2-2024-weaker-sales-minor-deviations-elsewhere?utm_source=finwire&utm_medium=RSS

Nyheter om Heliospectra

Läses av andra just nu

Om aktien Heliospectra

Senaste nytt